What are the effects of Dapagliflozin on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction?
The DEFINE-HF Trial was a multicenter, randomized, double-blind, placebo-controlled trial that evaluated the effects of Dapagliflozin on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction. The trial found that Dapagliflozin was associated with significant improvements in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, symptoms, and functional status at 12 weeks, as well as a reduction in hospitalizations and cardiovascular events at 24 weeks.